Abbott's new cancer agent has promising results in Phase 1 trial
The Phase II trial of the medicine, known as ABT-869, will begin by the end of the year in about 60 lung and 6...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
